Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Sat Dec 16 15:26:53 GMT 2023
by
admin
on
Sat Dec 16 15:26:53 GMT 2023
|
| Source Materials Class | ORGANISM |
| Source Materials Type | AUTOLOGOUS HUMAN |
| Source Materials State | LIVE ATTENUATED GENETICALLY MODIFIED |
| Source Materials Parent | |
| Part | BLOOD |
| Fraction Material Type | CELLS |
| Fraction Name | T CELL |
| Record UNII |
4MD2J2T8SJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
516015
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
515815
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
515715
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2387277
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
PRIMARY | |||
|
4MD2J2T8SJ
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
PRIMARY | |||
|
GH-165
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
PRIMARY | |||
|
4MD2J2T8SJ
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
PRIMARY | |||
|
C170439
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
PRIMARY | |||
|
11886
Created by
admin on Sat Dec 16 15:26:53 GMT 2023 , Edited by admin on Sat Dec 16 15:26:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
Agent Modifications
| Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
|---|---|---|---|---|---|
| CULTURE | ACTIVATION (CD3/CD28 ANTIBODIES) | IMMUNOLOGICAL | |||
| TRANSFECTION | RETROVIRAL TRANSFECTION | UNSPECIFIED SUBSTANCE | 0f2235db | ||
| CD4-/CD8- ENRICHMENT | CELL SEPARATION | ||||
| T ENRICHMENT (Removal of impurities) | CELL SEPARATION |